455 related articles for article (PubMed ID: 9396878)
1. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours.
Adams S; Baum R; Rink T; Schumm-Dräger PM; Usadel KH; Hör G
Eur J Nucl Med; 1998 Jan; 25(1):79-83. PubMed ID: 9396878
[TBL] [Abstract][Full Text] [Related]
2. Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours: comparison with the expression of the Ki-67 antigen.
Adams S; Baum RP; Hertel A; Schumm-Dräger PM; Usadel KH; Hör G
Nucl Med Commun; 1998 Jul; 19(7):641-7. PubMed ID: 9853344
[TBL] [Abstract][Full Text] [Related]
3. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings.
Adams S; Baum RP; Hertel A; Schumm-Draeger PM; Usadel KH; Hör G
Eur J Nucl Med; 1998 Sep; 25(9):1277-83. PubMed ID: 9724377
[TBL] [Abstract][Full Text] [Related]
4. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer.
Brandt-Mainz K; Müller SP; Görges R; Saller B; Bockisch A
Eur J Nucl Med; 2000 May; 27(5):490-6. PubMed ID: 10853802
[TBL] [Abstract][Full Text] [Related]
5. Comparison of ⁶⁸Ga-DOTATATE PET-CT, ¹⁸F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma.
Ozkan ZG; Kuyumcu S; Uzum AK; Gecer MF; Ozel S; Aral F; Adalet I
Nucl Med Commun; 2015 Mar; 36(3):242-50. PubMed ID: 25369749
[TBL] [Abstract][Full Text] [Related]
6. Intraoperative gamma probe detection of neuroendocrine tumors.
Adams S; Baum RP; Hertel A; Wenisch HJ; Staib-Sebler E; Herrmann G; Encke A; Hör G
J Nucl Med; 1998 Jul; 39(7):1155-60. PubMed ID: 9669386
[TBL] [Abstract][Full Text] [Related]
7. The role of positron emission tomography (PET) in diagnostics of gastroenteropancreatic neuroendocrine tumours (GEP NET).
Junik R; Drobik P; Małkowski B; Kobus-Błachnio K
Adv Med Sci; 2006; 51():66-8. PubMed ID: 17357280
[TBL] [Abstract][Full Text] [Related]
8. Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer.
Iwata M; Kasagi K; Misaki T; Matsumoto K; Iida Y; Ishimori T; Nakamoto Y; Higashi T; Saga T; Konishi J
Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):491-8. PubMed ID: 14666387
[TBL] [Abstract][Full Text] [Related]
9. [Somatostatin receptor scintigraphy in medullary thyroid carcinomas, GEP and carcinoid tumors].
Eising EG; Farahati J; Bier D; Knust EJ; Reiners C
Nuklearmedizin; 1995 Feb; 34(1):1-7. PubMed ID: 7724358
[TBL] [Abstract][Full Text] [Related]
10. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
11. Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma metastases.
Mucha SA; Kunert-Radek J; Pomorski L
Endokrynol Pol; 2006; 57(4):452-5. PubMed ID: 17006852
[TBL] [Abstract][Full Text] [Related]
12. Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer.
de Groot JW; Links TP; Jager PL; Kahraman T; Plukker JT
Ann Surg Oncol; 2004 Aug; 11(8):786-94. PubMed ID: 15289241
[TBL] [Abstract][Full Text] [Related]
13. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?
Behr TM; Gratz S; Markus PM; Dunn RM; Hüfner M; Schauer A; Fischer M; Munz DL; Becker H; Becker W
Cancer; 1997 Dec; 80(12 Suppl):2436-57. PubMed ID: 9406695
[TBL] [Abstract][Full Text] [Related]
14. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
15. Intraoperative use of gamma-detecting probes to localize neuroendocrine tumors.
Adams S; Baum RP
Q J Nucl Med; 2000 Mar; 44(1):59-67. PubMed ID: 10932602
[TBL] [Abstract][Full Text] [Related]
16. 18F-FLT and 18F-FDG positron emission tomography for the imaging of advanced well-differentiated gastro-entero-pancreatic endocrine tumours.
Giammarile F; Billotey C; Lombard-Bohas C; Le Bars D; Bournaud C; Masson S; Walter T; Houzard C; Scoazec JY; Hervieu V; Vuillez JP; Cornu C; Janier M; Borson-Chazot F
Nucl Med Commun; 2011 Feb; 32(2):91-7. PubMed ID: 21076344
[TBL] [Abstract][Full Text] [Related]
17. [Pre- and intraoperative localization of neuroendocrine tumors].
Adams S; Baum RP; Adams M; Wenisch H; Schumm-Draeger PM; Encke A; Usadel KH; Hör G
Acta Med Austriaca; 1997; 24(2):81-6. PubMed ID: 9273812
[TBL] [Abstract][Full Text] [Related]
18. Clinical value of technetium-99m-labeled octreotide scintigraphy in local recurrent or metastatic medullary thyroid cancers: a comparison of lesions with 18F-FDG-PET and MIBI images.
Sager S; Kabasakal L; Ocak M; Maecke H; Uslu L; Halaç M; Asa S; Sager G; Önsel Ç; Kanmaz B
Nucl Med Commun; 2013 Dec; 34(12):1190-5. PubMed ID: 24121313
[TBL] [Abstract][Full Text] [Related]
19. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer.
Grünwald F; Schomburg A; Bender H; Klemm E; Menzel C; Bultmann T; Palmedo H; Ruhlmann J; Kozak B; Biersack HJ
Eur J Nucl Med; 1996 Mar; 23(3):312-9. PubMed ID: 8599963
[TBL] [Abstract][Full Text] [Related]
20. [Contemporary nuclear medicine diagnostics of neuroendocrine tumors].
Srp Arh Celok Lek; 2015; 143(1-2):108-15. PubMed ID: 25845263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]